FDA approves Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women

Myfembree has been authorised for a treatment duration of up to 24 months. In the Phase III LIBERTY studies, 72.1% and 71.2% of women on Myfembree achieved the responder criteria, compared with 16.8% and 14.7% of women in the placebo groups at week 24, respectively.

Source:

PharmaTimes